基于iTRAQ蛋白质组学技术对前列腺癌血清标志物的筛查

Screening study for prostate cancer serum biomarkers based on iTRAQ proteomic technology

目的:应用同位素标记相对和绝对定量(iTRAQ)蛋白质组学技术筛选前列腺癌血清中的差异表达蛋白质,提供新的候选标志物。方法:收集4组患者的外周血清标本:良性前列腺增生(BPH)(n=10)、高级别前列腺上皮内瘤变(HGPIN)(n=10)、局限性前列腺癌(localized PCa)(n=10)以及伴有远处转移的前列腺癌(metastatic PCa)(n=10)。每组10例患者的血清样本进行等体积混合后,应用iTRAQ技术联合液相串联质谱分析(LC-ESI-MS/MS)对蛋白质进行鉴定和相对定量。结果:在患者外周血清中共鉴定到蛋白质825个。相对于良性前列腺增生,在前列腺癌组中表达差异在1.2倍以上的蛋白质13个,其中9个表达上调,4个表达下调。结论:基于iTRAQ技术的蛋白质组学方法有助于鉴定出前列腺癌相关的差异蛋白质,为进一步探索前列腺癌肿瘤标志物提供了新的思路和线索。

Objective: To screen the differentially expressed serum proteins in patients with prostate cancer( PCa)and benign prostatic disease using isobaric tag for relative and absolute quantitation( iTRAQ) technology. Methods:Serum samples were collected from 4 groups of patients: benign prostatic hyperplasia( BPH)( n = 10),high grade prostatic intraepithelial neoplasia( HGPIN)( n = 10),localized PCa( n = 10) and metastatic PCa( n = 10). Equal volumes of serum from 10 patients within the same group were mixed. Then iTRAQ proteomic approach was used to identify and quantify the proteins differentially expressed in these groups. Results: A total of 825 serum proteins were finally identified,among which 13 showed at least 1. 2 fold differences between the BPH and PCa group. Nine proteins were up-regulated and 4 proteins were down-regulated. Conclusion: A number of novel proteins associated with PCa could be identified based on iTRAQ proteomic approach,which provided new clues for the discovery of PCa biomarkers.